Associated Papers
CYP genetic polymorphism, and CYP3A inducers and inhibitors regulate apatinib metabolism: Consequences for drug exposure and toxicity risks.
Wang Z et al.
Toxicology and Applied Pharmacology, 2026
A model-based analysis of the CYP2C9 genotype effects on fluconazole inhibition using flurbiprofen, ketoprofen and tolbutamide as probe drugs.
Cheng S et al.
British Journal of Pharmacology, 2026
Assessing the influence of CYP2C9 and CYP2C19 genotypes on the metabolism of CBD-cannabis after controlled single and repetitive consumption.
Schulte J et al.
International Journal of Legal Medicine, 2026
Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.
Tremmel R et al.
Clinical Pharmacology and Therapeutics, 2026
Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients.
Shenoy PV et al.
Cancer Metastasis Reviews, 2025
An Investigational Study on the Role of ADME Agents' Genetic Variation on DD217 Pharmacokinetics and Safety Profile.
Sychev DA et al.
Pharmaceuticals (basel, Switzerland), 2025
The Genetic Polymorphisms of CYP2C9 and VKORC1 in the Saudi Population and Their Impact on Anticoagulant Management.
Al Hamad M
Medicina (kaunas, Lithuania), 2025
The role of genetic polymorphisms on drug response in Alzheimer's disease: a systematic review.
Climacosa FMM et al.
Bmc Medical Genomics, 2025
Quantitative Comparison of the Predictive Accuracy of Warfarin Pharmacogenetic Dosing Algorithms Derived From Population Data of Different Ethnicities in the Chinese Population.
Nan D et al.
Journal of Clinical Pharmacology, 2025
Pharmacogenetics and Molecular Ancestry of SLC22A1, SLC22A2, SLC22A3, ABCB1, CYP2C8, CYP2C9, and CYP2C19 in Ecuadorian Subjects with Type 2 Diabetes Mellitus.
Ortega-Ayala A et al.
Pharmaceuticals (basel, Switzerland), 2025
Impact of genetic variations on the pharmacokinetics, dose requirements, and clinical effects of propofol: a systematic review.
Gerstman MD et al.
British Journal of Anaesthesia, 2025
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
The Role of Pharmacogenetic Biomarkers in Pain.
Martin da Silva I et al.
Biomedicines, 2025
Hepatic Cytochrome P450 Enzymatic System Interaction With Platelet Function and Cardiovascular Outcomes-Pharmacogenomic Impact on Inter-Organ Communication.
Figueiral M et al.
Comprehensive Physiology, 2025
Modeling the Influence of CYP2C9 and ABCB1 Gene Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Losartan.
Babaev D et al.
Pharmaceutics, 2025
Inhibition Mechanism of Ketamine-Apatinib by CYP2C9 and 3A4: A Prediction of Possible Drug-Drug Interaction.
Zheng X et al.
Biopharmaceutics & Drug Disposition, 2025
Genetic Mutations and Small Bowel Ulcerating Disease: Role in Diagnosis?
Modi R et al.
Current Gastroenterology Reports, 2025
Molecular Ancestry Across Allelic Variants of SLC22A1, SLC22A2, SLC22A3, ABCB1, CYP2C8, CYP2C9, and CYP2C19 in Mexican-Mestizo DMT2 Patients.
Ortega-Ayala A et al.
Biomedicines, 2025
Contrastive sequence signatures between the both sides of a recombination spot reveal an adaptation at PPARD locus from standing variation for pleiotropy since out-of-Africa dispersal.
Shou W et al.
Bmc Genomics, 2025
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonylureas.
Wolthuis DFGJ et al.
European Journal of Human Genetics : Ejhg, 2025
Effects of fluconazole on the pharmacokinetics of celecoxib and its carboxylic acid metabolite in different CYP2C9 genotypes.
Cho CK et al.
Archives of Pharmacal Research, 2025
Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19.
Park HJ et al.
Archives of Pharmacal Research, 2025
Frequencies of CYP2C9 polymorphisms in a Syrian cohort.
Aldiban W et al.
Bmc Genomics, 2025
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
The impact of genetic variability on Alzheimer's therapies: obstacles for pharmacogenetic progress.
Cacabelos R et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
The relationship between CYP2C9 gene polymorphisms and azilsartan metabolism in vitro.
Bao SS et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data.
Litonius K et al.
Clinical Pharmacology and Therapeutics, 2025
Pharmacogenetics polygenic response score predicts outcomes in aspirin-treated stroke patients.
Ma RN et al.
Frontiers in Pharmacology, 2025
The impact of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin dose requirement in Saudi patients.
Jokhab S et al.
Frontiers in Pharmacology, 2025
Mathematical modeling of pharmacokinetics and pharmacodynamics of losartan in relation to CYP2C9 allele variants.
Babaev D et al.
Frontiers in Systems Biology, 2025
Role of pharmacogenomics for prevention of hypersensitivity reactions induced by aromatic antiseizure medications.
Alvarado AT et al.
Frontiers in Pharmacology, 2025
Prevalence of risk phenotypes associated with CYP2C9*2, *3, and VKORC1 c.-1639G>A genetic polymorphisms in world populations: implications in clinical practice.
Biswas M et al.
Frontiers in Pharmacology, 2025
A digital twin of glimepiride for personalized and stratified diabetes treatment.
Elias M et al.
Frontiers in Pharmacology, 2025
Application of Loading Dose Warfarin in Postpartum Women with Pulmonary Embolism - a Prospective, Randomized, Double-Blind Trial.
Huang W et al.
Drug Design, Development and Therapy, 2025
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial.
Roncato R et al.
Jama Network Open, 2024
Influence of CYP2C9 phenotypes on phenytoin plasma concentration in neurosurgical Brazilian patients.
Kurtz P et al.
Pharmacogenetics and Genomics, 2024
Comparative performance of pharmacogenetics-based warfarin dosing algorithms in Chinese population: use of a pharmacokinetic/pharmacodynamic model to explore dosing regimen through clinical trial simulation.
Shi K et al.
Pharmacogenetics and Genomics, 2024
Assessing the Performance of In silico Tools and Molecular Dynamics Simulations for Predicting Pharmacogenetic Variant Impact.
AlSaeed MJ et al.
Clinical Pharmacology and Therapeutics, 2024
Investigating the Correlation between Genotypes and Hepatic Protein Expression of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 Using Postmortem Tissue from a Danish Population.
Pedersen KW et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2024
Establishing national reference materials for genetic testing of cytochrome P450.
Jia Z et al.
Pharmacogenetics and Genomics, 2024
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs.
Manson LEN et al.
European Journal of Human Genetics : Ejhg, 2024
Polycyclic aromatic hydrocarbon and its adducts in peripheral blood: Gene and environment interaction among Chinese population.
Guo L et al.
Environment International, 2024
Phenotype-Genotype Correlation Applying a Cocktail Approach and an Exome Chip Analysis Reveals Further Variants Contributing to Variation of Drug Metabolism.
Böhm R et al.
Clinical Pharmacology and Therapeutics, 2024
Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients.
Zhang S et al.
Pharmacogenetics and Genomics, 2024
Major Genetic Drivers of Statin Treatment Response in African Populations and Pharmacogenetics of Dyslipidemia Through a One Health Lens.
Lusiki Z et al.
Omics : a Journal of Integrative Biology, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Stability of Anticoagulation Following Acenocoumarin in Stroke Patients: Role of Pharmacogenomics and Acquired Factors.
Dubey AK et al.
Annals of Indian Academy of Neurology, 2024
A physiologically-based pharmacokinetic/pharmacodynamic modeling approach for drug-drug-gene interaction evaluation of S-warfarin with fluconazole.
Geng K et al.
Cpt: Pharmacometrics & Systems Pharmacology, 2024
Association between gene polymorphisms and initial warfarin therapy in patients after heart valve surgery.
Liu Z et al.
Pharmacological Reports : Pr, 2024